Feiba 500 U & 1000 U 500 U & 1000 U Powder and solvent for solution for injection
PDF Leaflet Revision Date: 26 February 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment and prevention of bleeding in patients with haemophilia A or B with inhibitors.
Dosage (summary)
50-100 U/kg bodyweight, max 200 U/kg/day; adjust based on bleeding severity.
Special Populations
- Elderly
- Paediatric population
Pregnancy & Breastfeeding
Safety not established; increased risk of thrombosis in pregnancy.
Key Drug Interactions
- Antifibrinolytics
- Recombinant Factor VIIa
- Emicizumab
Contraindications
- Hypersensitivity
- DIC
- Acute thrombosis or embolism
Common side effects
- Hypersensitivity reactions
- Thrombosis
- Headache
- Nausea
Counselling Points
- Monitor for signs of hypersensitivity
- Do not exceed recommended doses
- Inform about potential thromboembolic risks
Serious warnings
- Risk of thromboembolic events
- Monitor for DIC
- Allergic reactions
On This Page
Connecting to Document Server
Decrypting and optimizing pharmaceutical leaflet...
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
